drugset

drugset / Trial / NCT05876572

Blood Naloxone Levels Following Intradermal Injection in Humans

NCT05876572 ↗

Phase 4 Withdrawn Johns Hopkins University DEKA S.r.l. · collab

NaSingle-groupOpen-labelOther

Summary

The main purpose of this study is to evaluate pharmacokinetics/pharmacodynamics of intradermal administration of naloxone in healthy adult subjects.

Timeline

Start: 2024-08
Primary completion: 2024-12
Completion: 2024-12

Outcome

Outcome not reported

Stopped: “Currently does not have active IRB status”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naloxone	Small molecule	8 mg	Other

Indications